Drug Topics

JANUARY 3, 2025

Researchers explored ideas of simplifying the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.

Vaccines 185

Vaccines Immunization 185

Fierce Healthcare

JANUARY 3, 2025

Mimicking prior federal and state investigations into drug manufacturers, health insurer Aetna is suing in Connecticut for rigging the generic drug market.

Insurance 145

Insurance 145

Pharmacy Times

JANUARY 2, 2025

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

145

145

PharmaVoice

JANUARY 2, 2025

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

126

126

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

DECEMBER 28, 2024

Check out this list of our top 5 most read infectious disease stories from the year 2024.

201

201

Fierce Healthcare

JANUARY 2, 2025

In this month's payer roundup, CVS faces antitrust questions from Congress as the company lays off more workers following a failed Medicaid bid in Kansas, Oscar Health CEO Mark Bertolini has a bold idea to remake health insurance and Johnson & Johnson is suing Express Scripts in a long-running lawsuit.

Insurance 141

Insurance 141

STAT

DECEMBER 30, 2024

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than a decade, the Congressional Budget Office (CBO) ventured to  estimate  the budgetary effects of such a policy for older Americans starting in 2026 for the very first time in a report published in October.  The CBO should be commended for conducting this comprehensive analysis.

129

129

Drug Topics

DECEMBER 31, 2024

Check out this list of our top 5 most read obesity stories from the year 2024.

187

187

The Checkup by Singlecare

JANUARY 3, 2025

Contrave is a brand-name medication approved by the U.S. Food and Drug Administration (FDA) for chronic (long-term) weight management in certain adults. It should be taken with a reduced-calorie diet and increased physical activity. As a combination drug that contains an opioid antagonist and antidepressant, it affects the brain to make you feel fuller and lower your appetite.

FDA 96

FDA 96

Pharmacy Times

JANUARY 1, 2025

Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.

139

139

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Healthcare

JANUARY 2, 2025

The group is concerned about understaffing, retention challenges and low pay. NYC H+H affiliates and the Doctors Council have been negotiating a new contract for 15 months.

114

114

STAT

DECEMBER 30, 2024

Work by device manufacturers to improve the performance of pulse oximeters on people with darker skin has progressed little since the Food and Drug Administration asked manufacturers in 2013 to voluntarily test the devices on more diverse skin tones, according to a study published Monday in JAMA. The study and a related editorial suggest clearer guidance, enforcement, and possibly legal action may be necessary to ensure the devices work well on all skin tones.

Documentation 135

Documentation FDA 135

pharmaphorum

JANUARY 3, 2025

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

105

105

Pharmacy Times

DECEMBER 31, 2024

The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.

139

139

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

The Checkup by Singlecare

JANUARY 2, 2025

As glucagon-like peptide-1 (GLP-1) receptor agonists continue to surge in popularity, the U.S. Food and Drug Administration approved the second generic in this class of medications: liraglutide (Victoza). This approval follows the generic version of Byetta (another GLP-1) in November. Generic liraglutide is the first once-daily generic GLP-1 injectable approved to treat Type 2 diabetes in patients 10 and older, alongside diet and exercise.

FDA 105

FDA Insurance Coverage Insurance 105

Med Ed 101

JANUARY 1, 2025

I’ve compiled this YouTube video to help candidates best prepare for their 2025 BCPS pharmacy exam. Pass rates continue to be in the 60% range so it is difficult to pass this exam. There are significant changes this year in the 2025 BCPS Exam compared to last spring. The content outline has shifted significantly. Here […] The post 2025 BCPS Pharmacy Exam – What You Need To Know appeared first on Med Ed 101.

105

105

pharmaphorum

JANUARY 3, 2025

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

FDA 105

FDA 105

Pharmacy Times

JANUARY 1, 2025

Administering first-dose antibiotics to septic shock patients via IV push rather than continuous infusion could improve the speed of antibiotic delivery and reduce logistical challenges.

131

131

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

DECEMBER 30, 2024

Axsome Therapeutics is moving ahead with plans to submit its Alzheimer’s disease treatment for Food and Drug Administration approval despite mixed results from two new clinical trial readouts.  Axsome, which is based in New York, announced Monday that its drug AXS-05 met the primary endpoint of one trial testing the therapy for agitation caused by Alzheimer’s, but failed to show statistical significance in another.

FDA 115

FDA 115

Pharmaceutical Technology

JANUARY 2, 2025

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

102

102

pharmaphorum

JANUARY 2, 2025

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

105

105

Pharmacy Times

JANUARY 3, 2025

Compliance is achievable for outpatient oncology practices with careful planning and execution.

123

123

Drug Topics

JANUARY 3, 2025

A study found that sending a letter to providers about standards of care and glucagon preparations could increase glucagon prescription rates.

98

98

Fierce Healthcare

JANUARY 2, 2025

HHS is backing away from a proposed rule that would've worked around an employer's religious objections to contraceptive coverage without cost sharing.

101

101

pharmaphorum

JANUARY 2, 2025

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market

100

100

Pharmacy Times

DECEMBER 31, 2024

Bispecific antibodies amivantamab and tarlatamab hold promise for patients.

132

132

Drug Topics

JANUARY 3, 2025

Researchers aimed to identify the barriers impeding HPV vaccine uptake since 2019 among US mid-adults aged 27 to 45.

Vaccines 98

Vaccines 98

The Checkup by Singlecare

DECEMBER 30, 2024

Sold under brand names such as Amvaz, Katerzia, Norliqva, and Norvasc , amlodipine is a medication that is FDA approved for the treatment of hypertension (high blood pressure), chronic stable angina (chest pain and pressure), vasospastic angina (coronary artery spasm), and coronary artery disease. It belongs to a class of medications called calcium channel blockers, which is further broken down into two classes: dihydropyridine calcium channel blockers and nondihydropyridine calcium channel bloc

Hospitals 98

Hospitals FDA 98

pharmaphorum

DECEMBER 31, 2024

Sangamo is 'surprised and disappointed' by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results

105

105

Pharmacy Times

JANUARY 3, 2025

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

122

122

Drug Topics

JANUARY 2, 2025

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the benefits of glucagon and why pharmacists should be able to prescribe it.

98

98

STAT

JANUARY 2, 2025

The new year ushered in a final slate of updates to the federal rules for how hospitals have to disclose their prices, and experts are optimistic the changes will make the data more helpful in identifying less expensive providers.   The updates are fairly straightforward. The government is requiring hospitals to include additional pieces of data to improve their consistency and make it easier to compare across hospitals.

Hospitals 114

Hospitals 114

pharmaphorum

JANUARY 2, 2025

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price

100

100